The Food and Drug Administration has accepted for review the Biologics License Application for inebilizumab for the treatment of patients with neuromyelitis optica spectrum disorder.
The FDA has approved Soliris (eculizumab; Alexion Pharmaceuticals, Inc) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
Long-term effect of eculizumab in patients with neuromyelitis optica spectrum disorder warrants further study, since there was no significant between-group difference in measures of disability progression.
Investigators analyzed racial differences in the clinical features of neuromyelitis optica spectrum disorder.
In the PREVENT study, the safety and efficacy of Soliris was compared to placebo in patients with AQP4 auto antibody-positive NMOSD (N=143).
The researchers suggest future prospective studies of acute relapse and disease-modifying treatment courses during and after pregnancy to ultimately improve treatment regimens for patients with NMOSD.
A proper MS diagnosis can only be made after obtaining imaging from the entire brain and understanding the clinical context.
Review a collection of clinical images and learn how to discern some of the most common and rare MS mimics on MRI.
In women with NMOSD, 42.9% of pregnancies ended in miscarriage compared with 12-24% in the general population.
